Vericiguat Misses Primary Target but Cuts Cardiovascular Deaths in Stable HFrEF
The VICTOR trial tested vericiguat in 6,105 stable heart failure patients, finding no significant reduction in the composite endpoint but a notable mortality signal.
Summary
The VICTOR trial enrolled 6,105 patients with heart failure and reduced ejection fraction (HFrEF) who had not experienced recent worsening. Patients were randomized to vericiguat or placebo for a median of 18.5 months. While the primary composite endpoint of cardiovascular death or heart failure hospitalization did not reach statistical significance (HR 0.93, p=0.22), cardiovascular death was 17% lower in the vericiguat group and all-cause death was 16% lower. These secondary findings are considered nominal due to the hierarchical testing structure. Symptomatic hypotension was more common with vericiguat. The results suggest vericiguat may not broadly benefit stable HFrEF patients, though the mortality signal warrants further investigation.
Detailed Summary
Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of cardiovascular morbidity and mortality worldwide. Vericiguat, a soluble guanylate cyclase stimulator, was previously approved to reduce cardiovascular death and hospitalization risk in HFrEF patients following a recent worsening event, based on the VICTORIA trial. A key unanswered question was whether the drug could also benefit the larger, more stable HFrEF population without recent deterioration.
The VICTOR trial addressed this directly in a rigorous double-blind, placebo-controlled, phase 3 design across 482 sites in 36 countries. Over 10,900 patients were screened and 6,105 were randomized 1:1 to oral vericiguat (target 10 mg daily) or placebo. Eligibility required HFrEF (LVEF ≤40%) but excluded those with recent heart failure hospitalization or IV diuretic use, distinguishing this population from prior vericiguat trials.
The primary composite endpoint of time to cardiovascular death or heart failure hospitalization did not differ significantly between groups (18.0% vericiguat vs. 19.1% placebo; HR 0.93, 95% CI 0.83–1.04; p=0.22). Because this threshold was not crossed, all secondary analyses are considered exploratory. Nevertheless, cardiovascular death occurred in 9.6% vs. 11.3% of patients (HR 0.83), and all-cause death in 12.3% vs. 14.4% (HR 0.84), both numerically favoring vericiguat.
Safety was broadly similar between arms; however, symptomatic hypotension occurred more frequently with vericiguat (11.3% vs. 9.2%). Serious adverse events were comparable overall (23.5% vs. 24.6%).
The trial confirms that vericiguat does not reduce composite cardiovascular events in stable HFrEF patients, limiting its role in this population under current regulatory frameworks. The intriguing mortality reduction signal, while hypothesis-generating, requires cautious interpretation given the trial's hierarchical design. Future analyses may help clarify whether specific subgroups derive meaningful benefit.
Key Findings
- Primary composite endpoint (CV death or HF hospitalization) not significantly reduced: HR 0.93, p=0.22.
- Cardiovascular death numerically lower with vericiguat: 9.6% vs. 11.3% (HR 0.83).
- All-cause death nominally reduced: 12.3% vs. 14.4% (HR 0.84, 95% CI 0.74–0.97).
- Symptomatic hypotension more frequent with vericiguat: 11.3% vs. 9.2%.
- Nearly half of participants (47.5%) had no prior heart failure hospitalization, representing a stable population.
Methodology
Double-blind, placebo-controlled, phase 3 RCT across 482 sites in 36 countries; 6,105 patients randomized 1:1 to vericiguat or placebo with median follow-up of 18.5 months. Primary endpoint was time to cardiovascular death or heart failure hospitalization analyzed in the intention-to-treat population using a hierarchical testing framework.
Study Limitations
Secondary and exploratory endpoints including mortality are nominal findings due to the pre-specified hierarchical testing structure and cannot support definitive conclusions. The trial excluded patients with recent HF worsening, limiting generalizability to the broader HFrEF population. Publication of only the abstract limits full assessment of subgroup analyses, adherence data, and potential effect modifiers.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.